Agentic Discovery of Non-Canonical Antimicrobial Peptides with AMPGAN v3

• URL: http://arxiv.org/abs/2606.17127v1
• Date: Mon, 15 Jun 2026 16:39:59 GMT
• Title: Agentic Discovery of Non-Canonical Antimicrobial Peptides with AMPGAN v3
• Abstract summary: We present AMPGAN v3, a conditional GAN that expands the generative vocabulary to D-amino acids and N/C-terminus modifications.<n>By separating adversarial and activity-aware supervision across two specialized discriminators, AMPGAN v3 substantially improves training stability.<n>We also present PepCraft, a multi-agent framework for end-to-end AMP discovery.
• Score: 11.081119264724094
• License: http://creativecommons.org/licenses/by/4.0/
• Abstract: Antimicrobial resistance causes to over a million deaths annually. Antimicrobial peptides (AMPs) are a promising solution, but generative AMP models are not yet ready to design peptides with non-natural amino acids and/or chemical modifications, which are essential for real-world peptide drugs. We present AMPGAN v3, a multi-objective conditional GAN that expands the generative vocabulary to D-amino acids and N/C-terminus modifications such as amidation. By separating adversarial and activity-aware supervision across two specialized discriminators, AMPGAN v3 substantially improves training stability and outperforms prior generative AMP models on external classifiers. We validated five candidates spanning three structural classes in vitro; two showed activity against Gram-positive strains, with the best candidate reaching MIC 8 μg/mL against B. subtilis. To support downstream curation, we further present PepCraft, a multi-agent framework for end-to-end AMP discovery in which a Planning Agent orchestrates specialized executors for generation, filtering, and verification. Its prioritization recommendations align with our in vitro outcomes. Together, these contributions let us examine, on a small but real scale, how generative and agentic AI compose in therapeutic peptide discovery. Code: https://github.com/marszzibros/AMPGANv3

Related papers

• ProDCARL: Reinforcement Learning-Aligned Diffusion Models for De Novo Antimicrobial Peptide Design [0.5361389213879222]
  Antimicrobial resistance threatens healthcare sustainability and motivates low-cost computational discovery of antimicrobial peptides (AMPs)<n>We introduce ProDCARL, a reinforcement-learning framework that couples a diffusion-based protein generator with sequence property predictors for AMP activity and peptide toxicity.<n>In silico experiments show ProDCARL increases the mean predicted AMP score from 0.081 after fine-tuning to 0.178.
  arXiv  Detail & Related papers  (2026-01-29T19:16:39Z)
• A deep reinforcement learning platform for antibiotic discovery [101.30486136547285]
  Antimicrobial resistance (AMR) is projected to cause up to 10 million deaths annually by 2050.<n>We present ApexAmphion, a deep-learning framework for de novo design of antibiotics.
  arXiv  Detail & Related papers  (2025-09-16T18:21:42Z)
• CL-MFAP: A Contrastive Learning-Based Multimodal Foundation Model for Molecular Property Prediction and Antibiotic Screening [9.162517838181683]
  We introduce CL-MFAP, an unsupervised contrastive learning (CL)-based multimodal foundation (MF) model specifically tailored for discovering small molecules with potential antibiotic properties (AP)<n>This model employs 1.6 million bioactive molecules with drug-like properties from the ChEMBL dataset to jointly pretrain three encoders.<n>The CL-MFAP outperforms baseline models in antibiotic property prediction by effectively utilizing different molecular modalities and demonstrates superior domain-specific performance when fine-tuned for antibiotic-related property prediction tasks.
  arXiv  Detail & Related papers  (2025-02-16T05:45:19Z)
• Artificial intelligence-driven antimicrobial peptide discovery [0.0]
  Antimicrobial peptides (AMPs) emerge as promising agents against antimicrobial resistance. AMPs provide an alternative to conventional antibiotics. Artificial intelligence (AI) revolutionized AMP discovery through both discrimination and generation approaches.
  arXiv  Detail & Related papers  (2023-08-21T14:02:14Z)
• xTrimoABFold: De novo Antibody Structure Prediction without MSA [77.47606749555686]
  We develop a novel model named xTrimoABFold to predict antibody structure from antibody sequence. The model was trained end-to-end on the antibody structures in PDB by minimizing the ensemble loss of domain-specific focal loss on CDR and the frame-aligned point loss.
  arXiv  Detail & Related papers  (2022-11-30T09:26:08Z)
• Accelerating Antimicrobial Peptide Discovery with Latent Structure [33.288514128470425]
  We propose a latent sequence-structure model for designing AMPs (LSSAMP) LSSAMP exploits multi-scale vector quantization in the latent space to represent secondary structures. Experimental results show that the peptides generated by LSSAMP have a high probability of antimicrobial activity.
  arXiv  Detail & Related papers  (2022-11-28T06:43:32Z)
• Graph-Based Active Machine Learning Method for Diverse and Novel Antimicrobial Peptides Generation and Selection [57.131117785001194]
  Large-scale screening of new AMP candidates is expensive, time-consuming, and now affordable in developing countries. We propose a novel active machine learning-based framework that statistically minimizes the number of wet-lab experiments needed to design new AMPs.
  arXiv  Detail & Related papers  (2022-09-18T14:30:48Z)
• Accelerating Inhibitor Discovery for Multiple SARS-CoV-2 Targets with a Single, Sequence-Guided Deep Generative Framework [47.14853881703749]
  We demonstrate the broad utility of a single deep generative framework toward discovering novel drug-like inhibitor molecules. To perform target-aware design, the framework employs a target sequence-conditioned sampling of novel molecules from a generative model. The most potent spike RBD inhibitor also emerged as a rare non-covalent antiviral with broad-spectrum activity against several SARS-CoV-2 variants.
  arXiv  Detail & Related papers  (2022-04-19T17:59:46Z)
• AntBO: Towards Real-World Automated Antibody Design with Combinatorial Bayesian Optimisation [53.43922443725598]
  We present AntBO: a Combinatorial optimisation algorithm enabling efficient in silico design of the CDRH3 region. To benchmark AntBO, we use the Absolut! software suite as a black-box oracle because it can score the target specificity and affinity of designed antibodies in silico. In under 200 protein designs, AntBO can suggest antibody sequences that outperform the best binding sequence drawn from 6.9 million experimentally obtained CDRH3s.
  arXiv  Detail & Related papers  (2022-01-29T12:03:04Z)
• HMD-AMP: Protein Language-Powered Hierarchical Multi-label Deep Forest for Annotating Antimicrobial Peptides [5.61222966894307]
  We build a diverse and comprehensive multi-label protein sequence database by collecting and cleaning amino acids from various AMP databases. We develop an end-to-end hierarchical multi-label deep forest framework, HMD-AMP, to annotate AMP comprehensively. After identifying an AMP, it further predicts what targets the AMP can effectively kill from eleven available classes.
  arXiv  Detail & Related papers  (2021-11-11T02:10:07Z)
• Accelerating Antimicrobial Discovery with Controllable Deep Generative Models and Molecular Dynamics [109.70543391923344]
  CLaSS (Controlled Latent attribute Space Sampling) is an efficient computational method for attribute-controlled generation of molecules. We screen the generated molecules for additional key attributes by using deep learning classifiers in conjunction with novel features derived from atomistic simulations. The proposed approach is demonstrated for designing non-toxic antimicrobial peptides (AMPs) with strong broad-spectrum potency.
  arXiv  Detail & Related papers  (2020-05-22T15:57:58Z)

This list is automatically generated from the titles and abstracts of the papers in this site.

This site does not guarantee the quality of this site (including all information) and is not responsible for any consequences.